Epithelioid Sarcoma Responds to the Oral EZH2 Inhibitor Tazemetostat.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-151
Abstract: Tazemetostat produced an overall response rate of 15% and median overall survival of 19.0 months. read more here.
Keywords: ezh2 inhibitor; sarcoma responds; responds oral; oral ezh2 ... See more keywords